visudyne
cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ögonsjukdomar - visudyne är indicerat för behandling av vuxna med exsudativ (våt) åldersrelaterad makuladegeneration (amd) med främst klassisk subfoveal koroidal kärlnybildning (cnv), eller vuxna med subfoveal koroidal kärlnybildning sekundärt till patologisk myopi.
beovu
novartis europharm limited - brolucizumab - wet macular degeneration - ögonsjukdomar - beovu är indicerat hos vuxna för behandling av neovaskulära (våt) åldersrelaterad makuladegeneration (amd).
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ögonsjukdomar - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ögonsjukdomar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
alfaxan 10 mg/ml injektionsvätska, lösning
zoetis animal health aps - alfaxalon - injektionsvätska, lösning - 10 mg/ml - alfaxalon 10 mg aktiv substans; hydroxipropylbetadex hjälpämne - alfaxalon - hund, katt
duramune bb vet frystorkat pulver och vätska till näsdroppar, suspension
zoetis finland oy - bordetella bronchiseptica, stam 92b, levande försvagad - frystorkat pulver och vätska till näsdroppar, suspension - sackaros hjälpämne; bordetella bronchiseptica, stam 92b, levande försvagad 6,32 - 8,74 log10 cfu aktiv substans - bordetellavaccin - hund
excenel vet. pulver till injektionsvätska, lösning
zoetis animal health aps - ceftiofurnatrium - pulver till injektionsvätska, lösning - ceftiofurnatrium 52,1 mg aktiv substans - ceftiofur - nöt
equip t vet. injektionsvätska, suspension
zoetis animal health aps - clostridium tetanitoxoid - injektionsvätska, suspension - aluminiumfosfat 5 mg adjuvans; clostridium tetanitoxoid 30 ie aktiv substans - clostridium - häst